B and T lymphocyte activation pathways

B and T lymphocyte activation pathways represent the complex, multi-step signaling networks required for the initiation and regulation of adaptive immune responses (Janeway et al., 2001). T-cell activation is primarily driven by the T-cell receptor (TCR) complex recognizing antigens presented by MHC molecules, a process that requires secondary costimulatory signals like CD28-CD80/86 to prevent anergy (Smith-Garvin et al., 2009). B-cell activation occurs through the B-cell receptor (BCR) upon antigen binding, often requiring T-cell-derived signals such as CD40 ligand for full differentiation into antibody-secreting plasma cells (Kurosaki et al., 2010). These pathways involve a cascade of intracellular events, including the activation of Src-family kinases and the subsequent mobilization of transcription factors like NFAT, NF-κB, and AP-1. Pharmacological modulation of these pathways is essential for treating autoimmune disorders, preventing transplant rejection, and advancing cancer immunotherapy through checkpoint inhibition (StatPearls, 2023). Because this entry refers to a broad biological process involving numerous distinct proteins rather than a single molecular target, it is classified as a pathway and is not a specific therapeutic target itself.

Other names

B-cell and T-cell activation signalingLymphocyte activationAdaptive immune signaling pathwaysImmune cell activation pathways

Drugs modulate these pathways by targeting specific receptors (e.g., TCR, BCR, CD20, PD-1) or intracellular signaling molecules (e.g., calcineurin, mTOR, JAKs) to either suppress or enhance immune cell activation, proliferation, and effector function.